EssilorLuxottica S.A. (ESLOY) Stock Price & Analysis
EssilorLuxottica S.A. (ESLOY) — price $96.86 (-2.38%), as of the Nov 19, 2026 trading session; market cap $88.8B.
Educational signal · not a buy or sell recommendation · How to read this
EssilorLuxottica S.A. · ESLOY · Healthcare · Medical - Instruments & Supplies
EssilorLuxottica S.A., established in Paris, France, in 1849, is a prominent global entity in the optical industry.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $96.86 | |
| Change on the day | -2.38% | |
| 52-week range | $79.27–$181.56 | |
| Market capitalisation | $88.8B | — |
| Price / earnings (trailing) | 33.11 | |
| Shares traded on the day | 21.2K | |
| Beta (volatility vs the S&P 500) | 0.55 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for EssilorLuxottica (ESLOY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 1, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is EssilorLuxottica (ESLOY), and what does it report?
Short answer
EssilorLuxottica S.A., established in Paris, France, in 1849, is a prominent global entity in the optical industry. Healthcare / Medical Instruments & Supplies SEC filing business address: 147 RUE DE Paris, Charenton LE Pont, I0, 94220. It employs 203,791 people and is led by Francesco Milleri. In Q2 FY2026 it reported revenue of €15.11B and net income of €1.60B. The market values it at $88.8B.
What do the latest results show for EssilorLuxottica (ESLOY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of €15.11B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | €15.11B | €1.60B | €1.72 (diluted) |
| Q4 FY2025 | €14.36B | €921M | €0.98 (diluted) |
| Q2 FY2025 | €14.02B | €1.39B | €1.50 (diluted) |
| Q4 FY2024 | €13.22B | €994M | €1.08 (diluted) |
What are the financial strengths and risks for EssilorLuxottica (ESLOY)?
Short answer · as of
The distress and quality screens read Altman Z 2.91 · Piotroski F 8. Trailing ratios: ROE 6.4% · ROA 3.8% · current ratio 0.89 · earnings yield 2.9% · free-cash-flow yield 4.5%.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Rich valuation — a P/E of 33.11 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ESLOY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ESLOY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about EssilorLuxottica (ESLOY)?
Common Questions About ESLOY (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
How do Varilux, Crizal and Transitions fit into EssilorLuxottica?
They are prescription-lens technologies within the lenses and optical instruments business, alongside corrective lenses, optician equipment and digital optical solutions. They show why EssilorLuxottica is more than a frame and sunglasses company.
Why does EssilorLuxottica sell laboratory machinery alongside Foster Grant readers?
The company participates across the vision-care chain, supplying consumers with readers while also equipping laboratories and optical manufacturers with surfacing and coating machinery. That combination links consumer brands with business-to-business production infrastructure.
What is the ESLOY stock price today?
The last price recorded for EssilorLuxottica S.A. (ESLOY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 1 from SEC filings and earnings calls, 14 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com